We will provide you with approaches and services tailored to your needs We provide business support in several therapeutic areas, especially emerging oncology therapies
Prioritized therapeutic areas
- Oncology
- Neurology
- Dermatology
- Respiratory
Prioritized therapeutic modalities and technology platforms
- Chimeric antigen receptor (CAR-T and CAR-NK) cell therapies
- Messenger RNA & Gene editing
- Antibody-drug conjugates
- Immune checkpoint inhibitors
- Breakthrough new platforms (Suppressor tRNA, …)
Clinical stage
- Early stage innovative technology platforms for drug discovery and drug development (NME)
- Clinical stage assets (Ph1, Ph2 or Ph3) with promising clinical outcomes and/or with breakthrough designation, fast track designation, RMAT designation or PRIME designation
- Breakthrough therapies/drugs marketed in EU and/or US with large market and need in CN and with good IP coverage in CN